Arecor Therapeutics gets second phase 1 trial for AT278 underway
News release
by
Arecor Therapeutics PLC
London, UK
|
March 27, 2023 03:00 AM Eastern Daylight Time
Arecor Therapeutics PLC (AIM:AREC) CEO Sarah Howell speaks to Proactive's Thomas Warner after announcing the dosing of the first patient in a new trial of the company's AT278 ultra-concentrated and rapid-acting insulin.
Howell explains what the trial means for Arecor as it works towards developing better solutions for people living with diabetes.
Contact Details
Proactive UK Ltd
+44 20 7989 0813
